Needham & Company LLC Reaffirms Buy Rating for G1 Therapeutics (NASDAQ:GTHX)

Needham & Company LLC restated their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research report report published on Wednesday morning, Benzinga reports. The firm currently has a $12.00 target price on the stock.

Separately, Wedbush reiterated an outperform rating and issued a $5.00 price objective (up from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

G1 Therapeutics Stock Performance

Shares of GTHX opened at $4.13 on Wednesday. G1 Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.00. The firm has a 50 day moving average of $3.85 and a 200 day moving average of $3.05. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.87 and a quick ratio of 3.45.

G1 Therapeutics (NASDAQ:GTHX) last issued its earnings results on Wednesday, February 28th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The business had revenue of $14.87 million for the quarter, compared to the consensus estimate of $12.83 million. During the same period last year, the business posted ($0.73) EPS. Analysts predict that G1 Therapeutics will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $4.62, for a total transaction of $132,132.00. Following the completion of the sale, the insider now directly owns 169,938 shares in the company, valued at approximately $785,113.56. The sale was disclosed in a document filed with the SEC, which is available through this link. 8.23% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On G1 Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Curi Wealth Management LLC lifted its holdings in G1 Therapeutics by 17.8% in the third quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock valued at $102,000 after acquiring an additional 10,700 shares during the period. Financial Advocates Investment Management bought a new stake in shares of G1 Therapeutics during the 4th quarter valued at about $39,000. Creative Financial Designs Inc. ADV increased its position in shares of G1 Therapeutics by 98.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after purchasing an additional 17,475 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in shares of G1 Therapeutics in the 4th quarter worth approximately $76,000. Finally, Jump Financial LLC purchased a new position in shares of G1 Therapeutics in the fourth quarter worth approximately $105,000. 24.21% of the stock is currently owned by hedge funds and other institutional investors.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.